|
|
|
Insider
Information: |
Meek David D. |
Relationship: |
|
City: |
West Lafayette |
State: |
IN |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
5 |
|
Direct
Shares |
174,742 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$8,946,539 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
174,742 |
|
|
Total
Value |
$8,946,539 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
6
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
5
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-113.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Endocyte Inc |
ECYT |
Chief Commercial Officer |
2014-02-06 |
7,500 |
2013-09-12 |
0 |
Premium* |
|
Baxalta Inc |
BXLT |
EVP and President, Onc... |
2016-06-03 |
0 |
2015-07-01 |
0 |
Premium* |
|
uniQure B.V. |
QURE |
Director |
2023-02-27 |
16,071 |
2019-01-25 |
0 |
Premium* |
|
Entasis Therapeutics Holdings Inc. |
ETTX |
Director |
2022-07-11 |
0 |
2021-04-01 |
0 |
Premium* |
|
Mirati Therapeutics, Inc. |
MRTX |
|
2023-01-20 |
151,171 |
2022-01-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
26 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ECYT |
Endocyte Inc |
Chief Commercial Officer |
|
2014-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
7,500 |
0 |
- |
|
BXLT |
Baxalta Inc |
EVP and President, Oncology |
|
2015-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
25,068 |
25,068 |
0 |
- |
|
BXLT |
Baxalta Inc |
EVP and President, Oncology |
|
2016-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
27,976 |
52,514 |
0 |
- |
|
BXLT |
Baxalta Inc |
EVP and President, Oncology |
|
2016-06-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(51,640) |
0 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2019-01-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,230 |
3,230 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,063 |
4,571 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,382 |
6,953 |
0 |
- |
|
ETTX |
Entasis Therapeutics Hold... |
Director |
|
2021-04-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
22,000 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
Chief Executive Officer |
|
2022-01-14 |
4 |
A |
$0.00 |
$0 |
D/D |
34,057 |
34,057 |
0 |
- |
|
ETTX |
Entasis Therapeutics Hold... |
Director |
|
2022-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
27,500 |
49,500 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2022-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,534 |
7,982 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2022-06-15 |
4 |
A |
$0.00 |
$0 |
D/D |
9,080 |
16,460 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
Chief Executive Officer |
|
2022-12-19 |
4 |
A |
$0.00 |
$0 |
D/D |
35,425 |
69,587 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
Chief Executive Officer |
|
2023-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
89,379 |
151,171 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2023-02-27 |
4 |
S |
$19.71 |
$7,667 |
D/D |
(389) |
16,071 |
0 |
% |
|
QURE |
uniQure B.V. |
Director |
|
2022-02-28 |
4 |
S |
$16.70 |
$10,053 |
D/D |
(602) |
7,380 |
0 |
% |
|
QURE |
uniQure B.V. |
Director |
|
2021-03-02 |
4 |
S |
$37.50 |
$18,938 |
D/D |
(505) |
6,448 |
0 |
% |
|
BXLT |
Baxalta Inc |
EVP and President, Oncology |
|
2015-09-02 |
4 |
D |
$35.03 |
$27,709 |
D/D |
(791) |
24,277 |
0 |
- |
|
BXLT |
Baxalta Inc |
EVP and President, Oncology |
|
2016-03-03 |
4 |
D |
$39.30 |
$36,470 |
D/D |
(928) |
51,586 |
0 |
- |
|
QURE |
uniQure B.V. |
Director |
|
2020-01-28 |
4 |
S |
$60.94 |
$44,903 |
D/D |
(722) |
2,508 |
0 |
% |
|
ETTX |
Entasis Therapeutics Hold... |
Director |
|
2022-07-07 |
4 |
D |
$2.20 |
$48,400 |
D/D |
(22,000) |
0 |
0 |
- |
|
ETTX |
Entasis Therapeutics Hold... |
Director |
|
2022-07-11 |
4 |
D |
$2.20 |
$60,500 |
D/D |
(27,500) |
0 |
0 |
- |
|
ECYT |
Endocyte Inc |
Chief Commercial Officer |
|
2013-09-12 |
4 |
OE |
$8.73 |
$87,300 |
D/D |
10,000 |
10,000 |
0 |
- |
|
MRTX |
Mirati Therapeutics, Inc. |
Chief Executive Officer |
|
2023-01-17 |
4 |
S |
$42.38 |
$134,715 |
D/D |
(3,179) |
61,792 |
0 |
% |
|
ECYT |
Endocyte Inc |
Chief Commercial Officer |
|
2013-09-12 |
4 |
S |
$15.50 |
$155,000 |
D/D |
(10,000) |
0 |
0 |
- |
|
26 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|